October 26, 2014 5:30 AM ET

Healthcare Providers and Services

Company Overview of Memorial Sloan-Kettering Cancer Center

Company Overview

Memorial Sloan-Kettering Cancer Center, a cancer hospital, provides cancer treatment services. It offers adult and pediatric cancer care services; specialized treatments and services, including adult blood and marrow stem cell transplantation, pediatric blood and marrow transplantation, and pathology consulting; and symptom management services, such as integrative medicine, palliative care and pain management, rehabilitation, dermatologic health, and cognitive testing. The company also provides services in the areas of counseling, dermatology, fertility, genetic testing and counseling, integrative medicine, nutrition, rehabilitation, resources for life after cancer program, sexual health, an...

1275 York Avenue

67th-68th Streets

New York, NY 10065

United States

Founded in 1884

Phone:

212-639-2000

Fax:

212-717-3299

Key Executives for Memorial Sloan-Kettering Cancer Center

Chief Executive Officer and President
Age: 61
Senior Vice President of Finance
Chief Investment Officer and Vice President
Chief Information Officer and Vice President of Information Systems
Senior Vice President and General Counsel
Compensation as of Fiscal Year 2014.

Memorial Sloan-Kettering Cancer Center Key Developments

Atara Biotherapeutics Enters into Immunotherapy Alliance with Memorial Sloan Kettering Cancer Center to Develop and Commercialize Allogeneic T-cell Therapies

Atara Biotherapeutics has entered into an exclusive option agreement with Memorial Sloan Kettering Cancer Center to develop and commercialize allogeneic T-cell therapies to treat certain cancers and persistent viral infections. As part of the deal, Atara will have the option to acquire a worldwide license to three clinical stage T-cell therapies. These therapies include T-cells activated against Epstein Barr Virus, or EBV (Phase 2); T-cells activated against cytomegalovirus, or CMV (Phase 2); and T-cells activated against Wilms Tumor 1, or WT1 (Phase 1). These three programs share a common technology under which third-party donor-derived whole blood is collected and enriched for T lymphocytes (T-cells), which are then exposed to certain antigens, and the resulting activated T-cells are characterized and stored for future therapeutic use. Under the deal, MSK will receive cash and Atara common stock in return for the exclusive option. In case Atara exercises its option to enter into the license deal, MSK will receive an upfront license payment and will be eligible to secure additional payments based on achievement of certain development, regulatory and sales-related milestones as well as royalty payments. Both the firms have agreed to collaborate on further research to develop additional cellular therapies, which may include T-cell therapies against other antigens and/or chimeric antigen receptor-modified T-cells, known as CAR-T.

Memorial Sloan-Kettering Cancer Center Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 01:30 PM

Memorial Sloan-Kettering Cancer Center Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 01:30 PM. Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States. Speakers: Isabelle Rivière, Director, Cell Therapy and Cell Engineering Facility.

MabVax Therapeutics Holdings, Inc. Enters into Agreements with Memorial Sloan Kettering Cancer Center and Juno Therapeutics

MabVax Therapeutics Holdings Inc. announced it has entered into agreements with Memorial Sloan Kettering Cancer Center and Juno Therapeutics for the development of novel therapeutic products using antibody targeting sequences derived from the fully-human antibodies discovered using the company's internally developed antibody discovery platform. Under the agreements, MabVax will supply unique targeting sequences from the fully-human antibodies to MSK. Pursuant to the agreement with MSK, researchers at MSK will conduct the early stage research and development of Chimeric Antigen Receptor (CAR) T-cell therapeutics using the MabVax antibody sequences and then test them both in vitro and in animal models with the objective of producing anti-cancer therapeutics targeting certain solid tumors. MabVax and Juno entered into an exclusive option agreement giving Juno the right to negotiate a license agreement for exclusive rights to any CAR T-cell therapeutic products using the antibody sequences provided to MSKCC.

Similar Private Companies By Industry

Company Name Region
Bioexpress, LLC United States
HCA Inc. United States
Metropolitan Lithotriptor Associates PC United States
SunStar Healthcare, Inc. United States
Texas Masonic Retirement Center United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Memorial Sloan-Kettering Cancer Center, please visit www.mskcc.org. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.